ENTITY

Immutep (IMM AU)

23
Analysis
Health CareAustralia
Immutep Limited operates as a biotechnology company. The Company focuses on developing novel immunotherapy treatments for cancer and autoimmune disease. Immutep offers its services worldwide.
more
Refresh
bullishImmutep
27 Sep 2018 15:44Issuer-paid

Immutep - A second big pharma collaboration for efti

Immutep has entered into a clinical trial collaboration and supply agreement with Merck/Pfizer to investigate the combination of its APC activator...

Share
bullishImmutep
30 Aug 2018 18:17Issuer-paid

Immutep - LAG-3 progress in-house and via partners

Immutep has reported encouraging progress from its in-house and partnered programs over the past few months. Interim data from the TACTI-mel combo...

Share
bullishImmutep
30 Aug 2018 17:54Issuer-paid

Immutep - LAG-3 progress in-house and via partners

Immutep has reported encouraging progress from its in-house and partnered programmes over the past few months. Interim data from the TACTI-mel...

Share
bullishImmutep
29 Mar 2018 18:16Issuer-paid

Immutep - Merck collaboration opens new opportunities

Immutep has entered a clinical trial collaboration and supply agreement with Merck & Co (MSD) for a Phase II study to evaluate eftilagimod...

Share
bullishImmutep
29 Mar 2018 16:46Issuer-paid

Immutep - Merck collaboration opens new opportunities

Immutep has entered a clinical trial collaboration and supply agreement with Merck & Co (MSD) for a Phase II study to evaluate eftilagimod...

Share
x